Abstract: The invention relates to new piperazine derivatives of the general formula ##STR1## in which R' and R.sup.2 each represents 1, 2 or 3 halogen atoms, which may be the same or different,R.sup.3 represents a hydrogen atom or 1, 2 or 3 halogen atoms, X represents a hydroxy, C.sub.1-4 alkoxy, phenylcarbamoyloxy or C.sub.1-4 alkylcarbamoyloxy group,Y represents a hydrogen atom or a C.sub.1-3 alkyl group, or X and Y together with the carbon atom to which they are linked represent a carbonyl group,m is 1, 2 or 3,n is 0 or 1, with the proviso that m+n is at most 3, and their acid addition and quaternary ammonium salts.Other features of the invention areprocesses for the preparation of compounds of formula I,pharmaceutical preparations comprising a compound of formula I.

Abstract: Piperazine derivatives of the general formula ##STR1## wherein R.sub.1 -R.sub.9 are the same or different and each represents a hydrogen or halogen atom or a lower alkyl or lower alkoxy group, n is 2 or 3 and X represents a group (CH.sub.2).sub.m (in which m is 1, 2, 3 or 4) or a group --CH.sub.2 --CH.dbd.CH--, having methylene linked to the piperazine group, and acid addition and quaternary ammonium salts thereof, are described.The compounds exhibit a strong specific dopaminergic activity.Also described are methods for their preparation and use as therapeutic agents in the form of therapeutic compositions.

Abstract: Piperazine derivatives of the general formula ##STR1## wherein R.sub.1 -R.sub.9 are the same or different and each represents a hydrogen or halogen atom or a lower alkyl or lower alkoxy group, n is 2 or 3 and X represents a group (CH.sub.2).sub.m (in which m is 1, 2, 3 or 4) or a group --CH.sub.2 --CH.dbd.CH--, having methylene linked to the piperazine group, and acid addition and quaternary ammonium salts thereof, are described.The compounds exhibit a strong specific dopaminergic activity.Also described are methods for their preparation and use as therapeutic agents in the form of therapeutic compositions.

Abstract: Diphenylmethoxyethylamines of the general formula ##STR1## in which R.sub.1 represents a fluorine, bromine or chlorine atom, R.sub.2 represents a hydrogen or fluorine atom and R.sub.3 represents a hydrogen, fluorine or chlorine atom, with the provisos that R.sub.3 is a hydrogen atom when R.sub.2 is a fluorine atom, R.sub.1 is a fluorine atom when R.sub.3 is a chlorine atom and R.sub.1 is a fluorine or bromine atom when R.sub.2 and R.sub.3 both are hydrogen atoms, and their non-toxic acid addition salts are disclosed. The compounds have dopaminergic properties and their use is indicated for treating the Parkinson syndrome. Compositions for such use are disclosed.

Abstract: Diphenylmethoxyethylamines of the general formula ##STR1## in which R.sub.1 represents a fluorine, bromine or chlorine atom, R.sub.2 represents a hydrogen or fluorine atom and R.sub.3 represents a hydrogen, fluorine or chlorine atom, with the provisos that R.sub.3 is a hydrogen atom when R.sub.2 is a fluorine atom, R.sub.1 is a fluorine atom when R.sub.3 is a chlorine atom and R.sub.1 is a fluorine or bromine atom when R.sub.2 and R.sub.3 both are hydrogen atoms, and their non-toxic acid addition salts are disclosed. The compounds have dopaminergic properties and their use is indicated for treating the Parkinson syndrome. Compositions for such use are disclosed.